H2020Докторантска мрежа2017–2021

VIRO-FLOW · Enabling Technologies and Drug Discovery: Continuous Flow Processes to Discover Novel Antiviral Inhibitors

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2017-11-01 → 2021-10-31
Финансиране от ЕС
743 619 €
Участници
2
Схема
MSCA-ITN-EID

Линиите свързват координатора с партньорите.

Накратко на български

Нови химични съединения за спиране на вируса на хепатит B се търсят чрез комбиниране на поточна химия и микрофлуидни тестове. Това помага за по-бързото и ефективното създаване на лекарства за лечение на широко разпространени заболявания.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Enabling Technologies and Drug Discovery: Continuous Flow Processes to Discover Novel Antiviral Inhibitors

The VIRO-FLOW project aimed to integrate the advantages of continuous flow chemistry with in vitro microfluidic bioassay technologies for the fast and efficient discovery of novel and innovative inhibitors of the Hepatitis B Virus (HBV). The efficient production of drugs represents a challenge for society, since we face novel problems such as the expanding elderly population and the need of new chemical entities (NCE) or new molecular entities (NME) for the treatment of various diseases of high prevalence such as Hepatitis B. This programme aimed to contribute to the development of innovative methodologies that would allow more efficient production of new compounds with anti-viral activity, specifically against HBV, for future transfer of technology and knowledge between different sectors with relevant economic impact. The global objective of this ITN-EID programme was to provide an innovative and high-level training in drug discovery and enabling technologies for 3 Early-Stage Researchers (ESRs), supported by a network of experts in anti-infective therapeutics, specifically virology and bacteriology in AiCuris, a pharmaceutical company; and the Institute of Chemical Research of Catalonia (ICIQ), a research center working on catalysis, with a special focus on sustainability (functionalization of small molecules, renewable energies, new uses for light in chemistry) using an integrated approach. ICIQ is highly committed to knowledge and technology transfer to the chemical, pharmaceutical and energy industrial sectors. When at ICIQ, the students were integrated in the Pericàs Laboratory and the technology development unit ERTFLOW, with ample expertise in flow chemistry. All three ESRs, successfully completed their training and individual projects leading to the awarding of a PhD title for each one of them. As a direct consequence of the outstanding work and excellent training received, all three fellows have already secured a qualified job in their field of expertise.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

VIRO-FLOW project aims to integrate the advantages of continuous flow chemistry with in vitro microfluidic bioassay technologies for the fast and efficient discovery of novel and innovative inhibitors of the Hepatitis B Virus (HBV). This programme aims to contribute to the development of innovative methodologies that allow more efficient production of new compounds with anti-viral activity, specifically against HBV, for future transfer of technology and knowledge between different sectors with relevant economic impact. The global objective of this ITN-EID programme is to provide an innovative and high-level training in drug discovery and enabling technologies for 3 Early-Stage Researchers (ESRs), supported by a network of experts in anti-infective therapeutics, specifically virology and bacteriology in AiCuris, a pharmaceutical company; and the Institute of Chemical Research of Catalonia (ICIQ), a research Institute focused on sustainable chemistry in the field of catalysis and flow chemistry (through its technology development unit ERTFLOW). This ITN will educate the next generation of well-prepared ESRs, providing them with the skills necessary to pursue successful careers in a rapidly emerging field that requires novel multidisciplinary technological development as well as it will also be the channel for educating well-trained researchers with the scientific, technical and entrepreneurial skills so highly needed in the drug discovery field.This goal will be achieved through industrial doctoral training that includes international, interdisciplinary and inter-sectorial mobility, and that integrates both academic and industrial contributions. The research programme is composed of three closely related projects in the research areas of medicinal chemistry (including organic and computational chemistry), molecular biology and protein biochemistry.

Оригинален текст от CORDIS (на английски).

Участници

  • FUNDACIO INSTITUT CATALA D'INVESTIGACIO QUIMICA · TARRAGONAКоординаторИспания
  • AICURIS ANTI-INFECTIVE CURES AG · WUPPERTALГермания

Връзки

Данни: CORDIS, © Европейски съюз